Wegovy and Mounjaro: How Medical Weight Management Works
This is a subtitle for your new post


Quick answer: Wegovy (semaglutide) and Mounjaro (tirzepatide) are prescription injections taken once a week that reduce appetite. They are used for medical weight management alongside diet and exercise. Wegovy acts on one gut hormone receptor (GLP-1). Tirzepatide acts on two (GLP-1 and GIP). In large trials, people lost on average roughly 15 percent of body weight with semaglutide and up to about 20 percent or more with tirzepatide over more than a year. Both drugs need a doctor's assessment, a gradual dose increase and ongoing follow-up.
What are Wegovy and Mounjaro?
Both drugs belong to a newer class of medicines that copy hormones your gut releases after you eat. Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy at a higher dose for weight management. Tirzepatide is sold as Mounjaro. In the United States, the weight-management version of tirzepatide is called Zepbound, and the FDA approved it for that use in November 2023.
In Korea, tirzepatide was first approved for type 2 diabetes and later for chronic weight management. Lilly began distributing Mounjaro to Korean wholesalers in August 2025, so it is now prescribed in Korea alongside Wegovy.
How does medical weight management with Wegovy or Mounjaro work?
These medicines act on the brain's appetite centers and slow how fast the stomach empties. Most people feel full sooner, think about food less and eat smaller portions. They do not burn fat on their own. Weight loss comes from eating fewer calories over time.
Treatment starts at a low dose that is raised every few weeks. This "titration" step lets the digestive system adjust and reduces nausea. For example, US labeling for tirzepatide raises the dose over several weeks or months toward a maintenance dose of 5, 10 or 15 mg once weekly. Wegovy works up to a maintenance dose of 2.4 mg once weekly.
Who are these medications meant for?
In the US, the approved weight-management labels cover adults with a body mass index (BMI) of 30 or higher. They also cover adults with a BMI of 27 or higher who have at least one weight-related condition, such as high blood pressure, type 2 diabetes or high cholesterol. Rules in other countries can differ. In Korea, a doctor decides whether you are eligible.
These drugs are not meant for cosmetic weight loss in people already at a healthy weight. They are not suitable for some people. In particular, the labels say not to use them if you or a family member has had medullary thyroid cancer, or if you have multiple endocrine neoplasia type 2 (MEN 2). They are also not suitable during pregnancy. A doctor should review your history of pancreatitis, gallbladder disease, kidney problems, eating disorders, depression and any diabetes medicines you take.
How much weight do people lose, and how fast?
In the main Wegovy trial, participants lost an average of 14.9 percent of body weight after 68 weeks. The placebo group lost 2.4 percent. In tirzepatide trials, the highest dose produced an average loss of up to about 22.5 percent after 72 weeks. Individual results vary widely. Some people lose much less, and a few lose more.
Weight loss is usually gradual. Most of it happens over the first year as the dose is raised. Weight often comes back after the medicine is stopped, especially if eating and activity habits have not changed. Many doctors see these drugs as long-term treatment rather than a short course.
What are the side effects and risks?
The most common side effects affect the digestive system:
- Nausea, vomiting, diarrhea or constipation
- Bloating, burping, heartburn and stomach pain
- Fatigue, headache and injection-site reactions
These are usually worst after each dose increase and often ease with time. Less common but serious risks listed in the labeling include pancreatitis, gallbladder problems such as gallstones, kidney injury from dehydration, serious allergic reactions and low blood sugar when combined with some diabetes medicines. Seek urgent care for severe, persistent abdominal pain (with or without vomiting), signs of an allergic reaction, or very little urine.
Fast weight loss can also cost muscle as well as fat. Doctors usually advise eating enough protein and doing regular strength exercise to protect muscle.
What does a medical weight management program usually include?
- A medical history, measurements and often blood tests before starting
- A dose plan with check-ins at each step up
- Diet guidance focused on protein, fiber and fluids
- An activity plan that includes resistance training
- A long-term plan for maintenance or tapering
If you are visiting Korea, think about continuity before you start. You will need a way to keep getting the medicine safely, keep it at the right temperature, and see a doctor at home who can manage side effects and dose changes. Rules on carrying prescription injections across borders differ by country, so check them before you travel.
Frequently asked questions
Is Mounjaro stronger than Wegovy?
In trials, tirzepatide produced greater average weight loss than semaglutide. That does not make it the right choice for everyone. Side effects, cost, availability and your health history all matter, and your doctor can help you weigh them.
Can I switch from Wegovy to Mounjaro?
Some people do switch, but only under medical supervision. There is limited formal research on the best way to switch. Your doctor will choose a starting dose based on what you were taking and how you tolerated it.
Will I regain weight when I stop?
Many people regain some or much of the weight after stopping. The risk is higher without lasting changes to diet and activity. Plan the end of treatment with your doctor rather than stopping suddenly on your own.
Are compounded or online versions safe?
Medicines bought without a prescription or from unverified sellers may be counterfeit or wrongly dosed. Use only products prescribed by a licensed doctor and dispensed by a legitimate pharmacy.
This article is for general information and does not replace a consultation with a doctor. Results and suitability vary from person to person.
Sources: FDA: FDA Approves New Medication for Chronic Weight Management; Drugs.com: FDA Approves Wegovy for Adults with Obesity; The Korea Times: New obesity drug Mounjaro launches in Korea









